46 results
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Unicycive Announces $50 Million Private Placement
4:28pm
clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Nov 23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
4:42pm
studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety and tolerability … clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
23 Oct 23
Other Events
11:12am
will enhance our safety data package from preclinical studies, and the efficacy data is referenced with Unicycive’s previously disclosed … program, two clinical studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety
8-K
EX-99.1
q7xf66gic1o383th0j
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
8-K
EX-99.1
aw5ld ose
14 Aug 23
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
9:19pm
8-K
EX-99.1
hmqbfg188 qwjv
29 Jun 23
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
5:50pm
8-K
EX-99.1
trnze 6s796txuzn
16 May 23
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
10:30am
8-K
EX-99.1
djxul 5eisfhhqhg
31 Mar 23
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
7:47am
8-K
EX-99.1
l12r9 igndmmlgfd
29 Dec 22
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
12:55pm
8-K
EX-99.1
1wls24ftj5hfq7tvahu
28 Dec 22
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
9:29am
8-K
EX-99.2
8223b9z one2pt0
28 Dec 22
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
9:29am
8-K
EX-99.1
cahrlh pj14m1
14 Nov 22
Unicycive Announces Third Quarter Financial Results and Provides Business Update
9:49am
S-3
EX-1.1
kr7t m0e7rpihju
15 Aug 22
Shelf registration
6:20pm